{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3691, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes date and ticker symbol.", "imagePath": "https://imgproxy.kitesheet.com/vroQgItOQM6NlazKJY60kIQq6U6_znoBkw9QTysMMhs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMWVlY2RjZjI2MWVkZWQ0ZTk5ZmZhODQwYzMwZTQ3NS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/1", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/sH__7t7b_1MGVxBxuP1FuiamQ1dr5CZbmvTSkzM8GuI/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMWVlY2RjZjI2MWVkZWQ0ZTk5ZmZhODQwYzMwZTQ3NS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/S5E6xLTpuy_Ti6oTyfXDHlllTNp5BPgNvUlMIv8WE9U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMWVlY2RjZjI2MWVkZWQ0ZTk5ZmZhODQwYzMwZTQ3NS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/J9-Ulm69pqGdaeLLRNoD4jl2BH1-Yd8Lnlr2RjNH3Q0/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9jMWVlY2RjZjI2MWVkZWQ0ZTk5ZmZhODQwYzMwZTQ3NS9wMDAxLnBuZw" }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/2", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/3", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-3", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/4", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-4", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/5", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-5", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 6, "from": 5, "beatId": "42618dfb-59ee-4c76-a3c9-c19d06e49d51", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 5-6: N-GENIUS Platform Overview", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/6", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-6", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 6, "from": 5, "beatId": "42618dfb-59ee-4c76-a3c9-c19d06e49d51", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 5-6: N-GENIUS Platform Overview", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "pain_points", "function": "frame_problem", "notes": "Uses a hub-and-spoke diagram to illustrate the central problem of neurotoxicity and its four primary negative consequences.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/7", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-7", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 7, "from": 7, "beatId": "50192313-d709-41c5-b095-c4dd0ced8ec2", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slide 7: Neurotoxicity Restricts CAR-T Adoption", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/8", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-8", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a diagram to map specific protein domains to their functional benefits.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/9", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-9", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/10", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-10", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/11", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-11", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "solution", "function": "present_solution", "notes": "Includes a scientific quote justifying the use of Glycine/Serine linkers.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/12", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-12", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "solution", "function": "present_solution", "notes": "Includes a cartoon liver character at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/13", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-13", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/14", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-14", "loopMatches": [ { "to": 14, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "7d11637b-9390-42ac-9fbe-a23167bc5c6a", "evidence": "Slides 7-14 discuss the limitations of current CAR-T therapies due to neurotoxicity", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapy?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/15", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-15", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative bar charts for transduction efficiency and toxicity markers, and flow cytometry data for anti-exhaustion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/16", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-16", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/17", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-17", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-day mark.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/18", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-18", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a causal chain framework to link cellular pathology to systemic organ damage.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/19", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-19", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes a disclaimer about cross-trial comparison limitations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/20", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-20", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a table structure to contrast patient segments and includes a bar chart representation for patient growth.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/21", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-21", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/22", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-22", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 22, "from": 11, "beatId": "b5fc59b7-baf6-490a-90d0-0d5b303c8e97", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competitive Analysis", "beatSlug": "sequoia-pitch-competition", "evidence": "Slides 11-22: Various competitive analysis slides", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes FDA approval precedents as a footnote to justify the clinical strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/23", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-23", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses a visual icon-grid to represent market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/24", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-24", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 24, "from": 24, "beatId": "1c5a010b-7fab-424a-b340-b7b4ea9efc11", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": null, "evidence": "Slide 24: Outpatient Access To NXC-201 Potentially Increases CAR-T Addressable Market by 10-20x", "position": 2, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null }, { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "Includes detailed clinical trial citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/25", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-25", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to separate milestones by drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/26", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-26", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "roadmap", "function": "show_traction", "notes": "The slide uses a standard pharmaceutical pipeline table format, categorizing assets by clinical vs. preclinical status and highlighting specific clinical trial results and regulatory designations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/27", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-27", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "why_now", "function": "argue_timing", "notes": "Includes a comparison table of clinical outcomes (ORR/CR/sCR) between NXC-201 and competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/28", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-28", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/29", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-29", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/30", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-30", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a complex table structure to compare patient demographics and clinical outcomes across three cohorts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/31", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-31", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/32", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-32", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a side-by-side comparison of two disease indications, each with its own clinical data points and relevant market benchmarks.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/33", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-33", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates deepening clinical responses over time for NXC-201 therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/34", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-34", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 34, "from": 18, "beatId": "59dea3e4-911d-4dc4-b5bf-44d94b3ffdaf", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Slides 18-34: Various traction slides", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "solution", "function": "present_solution", "notes": "Includes a complex biological pathway diagram and three supporting charts demonstrating efficacy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/35", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-35", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/36", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-36", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/37", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-37", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/38", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-38", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table compares CRS and ICANS incidence and management across three dosage groups (150x10^6, 450x10^6, and 800x10^6 cells).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/39", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-39", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide highlights specific toxicity data (CRS and ICANS) for a competitor product.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/40", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-40", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "comparison_table", "function": "compare_peers", "notes": "Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/41", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-41", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/42", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-42", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights a competitive advantage for NXC-201 regarding patient eligibility.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/43", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-43", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 48, "slideType": "roadmap", "function": "plan_implementation", "notes": "Shows two parallel clinical development tracks: monotherapy and combination with tislelizumab.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/48", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-48", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 49, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/49", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-49", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 50, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-flow style layout to connect the platform's core capabilities to specific product outputs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/50", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-50", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 51, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a '3 Pillars' framework to explain the platform foundation, followed by a product-specific breakdown.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/51", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-51", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 52, "slideType": "solution", "function": "present_solution", "notes": "Includes a comparative size diagram of the drug vs IgG antibody and a Kaplan-Meier survival curve.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/52", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-52", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 53, "slideType": "traction", "function": "show_traction", "notes": "Includes two distinct sets of preclinical charts (tumor volume and survival curves) with detailed methodology in footnotes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/53", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-53", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 54, "slideType": "solution", "function": "present_solution", "notes": "Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/54", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-54", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 55, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/55", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-55", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 56, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/56", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-56", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 57, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a side-by-side comparison structure to explain two distinct proprietary platforms.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/57", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-57", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 58, "slideType": "product_demo", "function": "plan_implementation", "notes": "The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/58", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-58", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 59, "slideType": "comparison_table", "function": "compare_peers", "notes": "Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/59", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-59", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 60, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/60", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-60", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 61, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/61", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-61", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 62, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a combination of expert testimonials and a comparative clinical trial table to validate the outpatient therapy thesis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/62", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-62", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 63, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/63", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-63", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 64, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar-grouped chart format to highlight the efficacy gap between established treatments and placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/64", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-64", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }